Document Detail


Retrovirally mediated delivery of angiotensin II type 1 receptor antisense in vitro and in vivo.
MedLine Citation:
PMID:  10565039     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In spite of excellent drugs that are available for the control of hypertension, the pharmacological approach has major disadvantages including compliance, side effects, and inability to cure the disease. In the present chapter we provide evidence that a gene therapy concept based on the inhibition of the RAS at a genetic level, with the use of an antisense to the AT1R, is an exciting and viable approach for long-term control of hypertension without the disadvantages inherent in pharmaceutical therapy. A retrovirus-based vector has been used to deliver AT1R-AS in Ang II target tissues both in vitro and in vivo. The transduction efficiency is high and leads to the attenuation of Ang II action in vitro and prevention of hypertension in the SH rat, a model for primary human hypertension. These studies have unveiled a new avenue in which a similar approach could be attempted in the reversal of hypertension in adult animals.
Authors:
H Wang; D Lu; P Y Reaves; M J Katovich; M K Raizada
Related Documents :
12877769 - Intravenous angiotensin ii does not affect dynamic baroreflex characteristics of the ne...
22243149 - Search for sub-ev mass solar axions by the cern axion solar telescope with ^{3}he buffe...
12074359 - Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension.
6476129 - Central nervous system action of angiotensin during onset of renal hypertension in awak...
4042119 - Inhibition of the baroreceptor heart rate reflex by angiotensin ii in normal man.
9609089 - Pressure overload induces cardiac hypertrophy in angiotensin ii type 1a receptor knocko...
22445569 - Genetic variants associated with adult blood pressure and kidney function do not affect...
9087609 - Correlation between myocardial contractile force and cytosolic inorganic phosphate duri...
24665249 - Anesthetic management of descending thoracic aortobifemoral bypass for aortoiliac occlu...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Methods in enzymology     Volume:  314     ISSN:  0076-6879     ISO Abbreviation:  Meth. Enzymol.     Publication Date:  2000  
Date Detail:
Created Date:  1999-12-06     Completed Date:  1999-12-06     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0212271     Medline TA:  Methods Enzymol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  581-90     Citation Subset:  IM    
Affiliation:
Department of Physiology, University of Florida College of Medicine, Gainesville 32610, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
DNA, Antisense / therapeutic use*
Drug Delivery Systems
Genetic Vectors*
Hypertension / drug therapy*
Rats
Rats, Inbred SHR
Rats, Inbred WKY
Receptor, Angiotensin, Type 1
Receptor, Angiotensin, Type 2
Receptors, Angiotensin / genetics*
Retroviridae*
Grant Support
ID/Acronym/Agency:
HL-56921/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/DNA, Antisense; 0/Receptor, Angiotensin, Type 1; 0/Receptor, Angiotensin, Type 2; 0/Receptors, Angiotensin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Use of antisense techniques in rat renal medulla.
Next Document:  New ideas for indirect revascularization surgery for moyamoya disease